Noxopharm (ASX: NOX) confirms the presentation of clinical data concerning NOX66 (Veyonda®) to the 46th Annual Scientific Meeting of the Clinical Oncology Society of Australia (12th-14th November 2019). The data concerns LuPIN trial data and is being presented by a team of researchers at St Vincent’s Hospital, Sydney and the Garvan Institute of Medical Research.
For more information, download the attached PDF.
Download this document
